BioMarin presents new VOXZOGO data at ASBMR 2026
BioMarin will present new data from 13 studies, including a randomized, double-blind, placebo-controlled trial on VOXZOGO's effect on foramen magnum and craniocervical junction growth in children with achondroplasia. The company will also share data on the investigational long-acting medicine BMN 333 and on VOXZOGO's potential use in hypochondroplasia, for which it has submitted a supplemental New Drug Application.
Primary source
Company press release (PR Newswire), October 9, 2026
BioMarin Presents New Data Advancing Understanding of Achondroplasia and Hypochondroplasia Treatment at the American Society for Bone and Mineral Research Annual Meeting
Machine-summarized from the source above; not independently reported. How we use automation